The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-15. Anything still debated is marked as such rather than presented as settled.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
=== Professionelle Führungsperson === Lebenslanges Lernen Pflegen bzw. erhöhen der klinischen Standards durch kritisches, reflektiertes und evidenzbasiertes Handeln in der Praxis; kontinuierlicher Prozess des Lernens und Lehrens in Zusammenarbeit mit anderen Betreuern und Verantwortlichen; das Rollenverständnis geht von lebenslanger Weiterbildung aus, da die Funktion in einem Team nur so zur Aufrechterhaltung eines optimalen Ansatzes der Servicebereitstellung möglich ist; Reflexion der Praxis und Entwicklung von Fähigkeiten und Fertigkeiten sowie kritische Analyse der Praxis und Forschungsevidenz; Identifikation von Lernzielen, Entwicklung zur optimalen Weiterbildung und Wissenserwerb, Gebrauch verschiedener Lernmethoden, professionelle, einem Masterstudiengang adäquate Entwicklung des eigenen Lernfortschritts Professionalismus und Management Zeit-, Ressourcen- und Personalmanagement mit professionellen, ethischen und juristischen Fähigkeiten; erweitern des professionellen Handelns und eigener Exzellenz in verschiedenen (sportlichen) Umgebungen mit Erholungs- bzw. Sportbezug; interdisziplinäres Verknüpfen verschiedener Berufsfelder; stetiger Personal- und Servicebezug; Anerkennung der landeshoheitlichen, (inter-)nationalen Vorgaben; strategische Planungsziele; rechtliche Grundlagen; Servicemanagement-Gedanke; ethischer Arbeitsansatz; Schaffung positiver Lernumgebungen
=== Innovator === Forschungsergebnisse in die tägliche Arbeit einbeziehen Evaluation der Praxis und neuer Informationen; Identifizieren von Fragestellungen und Ansätzen für folgende (Forschungs-)Studien in verschiedenen Bereichen; kritische Evaluation und Reflexion in Bezug zur Rolle des Ratgebers sowie Fallmanagers und allen Arbeitsbereichen; kontinuierliche Evaluation und Entwicklung der eigenen Praxis; karriere- und schwerpunktbezogene Forschungsinhalte verfolgen; Beteiligung anstreben
=== Interdisziplinäre Führungsperson bzw. Innovator === Verbreitung von Wissen und bestmöglichen Handlungsstrategien Verbreiten neuen Wissens an andere Betreuer und Entscheidungsträger mit vielzähligen Möglichkeiten von Medien, auf Kongressen etc.
=== Interdisziplinärer Innovator bzw. Ratgeber === Erweiterung der Anwendungen durch Innovation Verbesserung der eigenen und Praxis sowie Beteiligter durch angemessene Einbeziehung neuen Wissens und von Innovationen in einem multidisziplinären Ansatz und Entscheidungsprozess; Einfluss- sowie Teilnahme auf die Ausrichtung von Forschungsgebieten und innovativer Projekte zur Unterstützung der Rolle des Ratgebers zur individuellen Interaktion, in multidisziplinären Kontexten, zur Qualitätssicherung von Serviceleistungen und strategischen Entwicklungsschritten; Zugang zu kontinuierlich entwickelnden Quellen schaffen; Bezug zu Forschungsinhalten und Innovationen der Sportphysiotherapie und zugehöriger Felder herstellen; Förderung von Wissenschaft und Forschung und deren spezifischen Feldern; kritische und reflektierende Betrachtung und Diskussion neuer Ideen und bestehender Veränderungen; Einbezug dieser in die Praxis, Weiterbildung und Lehre; Innovationen werden in den Entscheidungsfindungsprozess einbezogen und auf verschiedenen Leveln (im Sport) bedacht.
Sources: de.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.